SGLT2 inhibitors exert a variety of effects on the kidney, directly and indirectly linked to reduced glucose reabsorption, providing acute and chronic nephro-protective effects that reduce progression and may partially reverse the characteristic markers of diabetic kidney disease. Here, SLC5A2 is linked to diabetic kidney disease.